Related Experiment Video

Updated: Jun 23, 2026

Ambulatory ECG Recording in Mice
08:00

Ambulatory ECG Recording in Mice

Published on: May 28, 2010

Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac

Hajime Funakoshi1, Tung O Chan, Julie C Good

  • 1Center for Translational Medicine, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA.

Circulation
|November 8, 2006
PubMed

Insights

Overexpressing adenosine receptors (ARs) in the heart can cause dilated cardiomyopathy and death. However, delaying A1-AR expression until adulthood reduces but does not eliminate cardiac pathology, offering insights into heart failure.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Adenosine Receptor Signaling

Background:

  • Adenosine receptors (ARs), specifically A1-AR and A3-AR, are linked to adenosine-mediated cardioprotection.
  • Paradoxically, A1-AR and A3-AR overexpression correlate with altered cardiac phenotypes.
  • The temporal dynamics of AR signaling in cardiac remodeling require further investigation.

Purpose of the Study:

  • To investigate the temporal relationship between A1-AR signaling and cardiac remodeling.
  • To assess the effects of controlled A1-AR overexpression in a cardiac-specific manner.

Main Methods:

  • Utilized a cardiac-specific, tetracycline-regulated promoter for controlled A1-AR overexpression in mice.
  • Examined phenotypes, survival rates, cardiac function, and gene expression under constitutive and delayed A1-AR induction.
  • Assessed the impact of A1-AR induction discontinuation on cardiac dysfunction.

Main Results:

  • Constitutive A1-AR overexpression led to dilated cardiomyopathy, reduced ventricular function, decreased heart rate, and death within 6-12 weeks.
  • Delayed A1-AR expression until adulthood improved survival (>90% at 30 weeks) and prevented immediate cardiac dysfunction.
  • Late A1-AR induction still resulted in mild cardiomyopathy, accelerated hypertrophy, and dilatation under pressure overload, with decreased Akt phosphorylation and fibrosis.

Conclusions:

  • Robust, constitutive A1-AR overexpression induces dilated cardiomyopathy.
  • Delayed A1-AR expression ameliorates, but does not fully prevent, cardiac pathology.
  • The inducible A1-AR mouse model offers insights into adenosine signaling in heart failure and the consequences of selective vs. nonselective AR activation.
Abstract

Related Concept Videos

Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...